Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19
Audun Lier, Jessica Tuan, Matthew W. Davis, Nathan Paulson, Dayna McManus, Sheldon Campbell, David R. Peaper, Jeffrey Topal
Abstract
The SARS-CoV-2 virus has emerged and rapidly evolved into a current global pandemic. Although bacterial and fungal coinfections have been associated with COVID-19, little is known about parasitic infection. We report a case of a COVID-19 patient who developed disseminated strongyloidiasis following treatment with high-dose corticosteroids and tocilizumab. Screening for Strongyloides infection should be pursued in individuals with COVID-19 who originate from endemic regions before initiating immunosuppressive therapy.
Topics & Concepts
StrongyloidiasisStrongyloides stercoralisCoronavirus disease 2019 (COVID-19)PandemicTocilizumabCoinfectionStrongyloidesMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyVirology2019-20 coronavirus outbreakIntensive care medicineHuman immunodeficiency virus (HIV)Internal medicineHelminthsOutbreakInfectious disease (medical specialty)Rheumatoid arthritisDiseaseParasites and Host InteractionsAmoebic Infections and TreatmentsParasite Biology and Host Interactions